Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Nalbuphine ER: Completed Phase II/III enrollment

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa …

    Published on 4/13/2015
  • Ornithine phenylacetate: Phase IIb amended

    Ocera Therapeutics Inc. (NASDAQ:OCRX), Palo Alto, Calif. Product: Ornithine phenylacetate (OCR-002) Business: Hepatic Molecular target: NA Description: Ammonia scavenger Indication: Treat acute hepatic encephalopathy …

    Published on 4/13/2015
  • Remimazolam: Phase III started

    Hana Pharmaceutical Co. Ltd., Seoul, South Korea Humanwell Healthcare Group Co. Ltd. (Shanghai:600079), Wuhan, China Paion AG (Xetra:PA8), Aachen, Germany PendoPharm Inc., Montreal, Quebec R-Pharm CJSC, Moscow, Russia …

    Published on 4/13/2015
  • REP 2139-Ca: Completed Phase II enrollment

    Replicor Inc., Montreal, Quebec Product: REP 2139-Ca Business: Infectious Molecular target: NA Description: Nucleic acid polymer Indication: Treat chronic HBV and HDV co-infection Endpoint: Safety; reduction in …

    Published on 4/13/2015
  • Rivipansel: Phase III start

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rivipansel (GMI-1070, PF-06460031) Business: Hematology Molecular target: E selectin (SELE) (CD62E); P selectin (SELP)…

    Published on 4/13/2015
  • Telotristat etiprate: Completed Phase III enrollment

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Product: Telotristat etiprate (LX1032, LX1606) Business: Endocrine/Metabolic Molecular target: Tryptophan hydroxylase 1 (TPH1) (TPH) Description: …

    Published on 4/13/2015
  • Topical NS2: Phase II started

    Aldeyra Therapeutics Inc. (NASDAQ:ALDX), Burlington, Mass. Product: Topical NS2 Business: Dermatology Molecular target: NA Description: Small molecule that traps and allows for the disposal of free aldehydes Indication:…

    Published on 4/13/2015
  • AKB-6548: Completed Phase II enrollment

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 4/6/2015
  • AST-OPC1: Phase I/IIa started

    Asterias Biotherapeutics Inc. (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1 Business: Neurology Molecular target: NA Description: Human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells Indication…

    Published on 4/6/2015
  • AuriPro: Phase II started

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: AuriPro (formerly OTO-201) Business: Infectious Molecular target: DNA gyrase Description: Sustained-release gel formulation of ciprofloxacin Indication: Treat acute…

    Published on 4/6/2015
  • Aurix System: Phase IV started

    Nuo Therapeutics Inc. (OTCQX:NUOT), Gaithersburg, Md. Rohto Pharmaceutical Co. Ltd. (Tokyo:4527), Osaka, Japan Product: Aurix System, AutoloGel System Business: Dermatology Molecular target: NA Description: Device that …

    Published on 4/6/2015
  • Bardoxolone methyl: Phase II started

    Reata Pharmaceuticals Inc., Irving, Texas AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: Bardoxolone methyl (RTA 402) Business: Renal Molecular target: Nuclear …

    Published on 4/6/2015
  • Cis-UCA Eye Drops: Completed Phase II enrollment

    Herantis Pharma plc (HSE:HRTIS), Helsinki, Finland Product: Cis-UCA Eye Drops Business: Ophthalmic Molecular target: Serotonin (5-HT2A) receptor Description: Viscous formulation of cis-urocanic acid, a serotonin (5-HT2A…

    Published on 4/6/2015
  • CMB305: Phase Ib started

    Immune Design Corp. (NASDAQ:IMDZ), Seattle, Wash. Product: CMB305, ID-CMB305 Business: Cancer Molecular target: NA Description: Combination of LV305, a lentiviral vector engineered to deliver antigen-carrying nucleic …

    Published on 4/6/2015
  • Farletuzumab: Phase II started

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Farletuzumab (MORAb-003) Business: Cancer Molecular target: Folate receptor 1 (FOLR1) (FR-alpha) Description: Humanized IgG1 antibody targeting the folate receptor 1 (…

    Published on 4/6/2015
  • Iluvien fluocinolone acetonide intravitreal implant: Completed Phase III enrollment

    Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga. pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Mass. Specialised Therapeutics Australia Pty. Ltd., Melbourne, Australia Product: Iluvien fluocinolone acetonide …

    Published on 4/6/2015
  • MAT9001: Completed Phase I/II enrollment

    Matinas BioPharma Holdings Inc. (OTCQB:MTNB), Bedminster, N.J. Product: MAT9001 Business: Endocrine/Metabolic Molecular target: NA Description: Next-generation omega-3 fatty acids, including docosapentaenoic acid (DPA) …

    Published on 4/6/2015
  • MT-3724: Phase I started

    Molecular Templates Inc., Georgetown, Texas Product: MT-3724 Business: Cancer Molecular target: CD20 Description: Engineered toxin body (ETB) against CD20 Indication: Treat non-Hodgkins lymphoma (NHL) Endpoint: Safety; …

    Published on 4/6/2015
  • NuQ tests: Pilot trial started

    VolitionRx Ltd. (NYSE-M:VNRX), Singapore Product: NuQ tests Business: Diagnostic Molecular target: NA Description: Family of non-invasive blood tests for nucleosomes Indication: Detect prostate cancer Endpoint: Detect …

    Published on 4/6/2015
  • NVN1000: Completed Phase IIb enrollment

    Novan Inc., Durham, N.C. Product: NVN1000, SB204 Business: Dermatology Molecular target: Androgen receptor Description: Nitric oxide (NO)-releasing compound Indication: Treat acne vulgaris Endpoint: Absolute change in …

    Published on 4/6/2015
  • SYN-004: Phase IIa started

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-004 (formerly P3A) Business: Infectious Molecular target: NA Description: Second-generation, oral beta lactamase (LACTB) that binds with and neutralizes…

    Published on 4/6/2015
  • Anti-IL-6R: Phase IIb started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Anti-IL-6R (ALX-0061) Business: Autoimmune Molecular target: Interleukin-6 (IL-6) receptor (CD126) Description: Nanobody …

    Published on 3/30/2015
  • AZP-531: Phase IIa started

    Alize Pharma, Lyon, France Product: AZP-531 Business: Endocrine/Metabolic Molecular target: Ghrelin Description: Unacylated ghrelin analog Indication: Treat Prader-Willi syndrome Endpoint: Safety; effects on fullness/…

    Published on 3/30/2015
  • CLS-TA: Phase II started

    Clearside Biomedical Inc., Alpharetta, Ga. Product: CLS-TA, CLS-1001 Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR) Description: Triamcinolone acetonide delivered using the companys ocular …

    Published on 3/30/2015
  • DPX-Survivac: Phase II started

    Immunovaccine Inc. (TSX:IMV), Halifax, Nova Scotia Product: DPX-Survivac Business: Cancer Molecular target: Survivin (BIRC5) Description: Vaccine comprising survivin (BIRC5)-based peptide antigens formulated using …

    Published on 3/30/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993